Literature DB >> 7535056

Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of Hoechst 33258 analogues.

R Gupta1, H Wang, L Huang, J W Lown.   

Abstract

The design, synthesis and biological evaluation of a series of bis-benzimidazole analogues of Hoechst 33258 bearing nitrogen mustard moieties is described. The novel compounds show clear evidence of interstrand cross-linking of linear lambda DNA, in contrast to their distamycin nitrogen mustard counterparts. Interference of the cross-linking reaction by the minor groove-selective distamycin suggests that this process takes place in the minor groove of DNA. Sequence preferential alkylation is revealed by high-resolution polyacrylamide gel electrophoresis and autoradiography. Alkylation occurs predominantly at the 5'-A or 5'-G termini of mixed sequences, determined largely by the sequence-recognizing properties of the bis-benzimidazole carrier moiety. An analysis of the frequency of bases around the alkylation sites reveals marked individual base preferences, especially for A at -3 and +3 positions. All of the compounds tested showed cytotoxic properties against the human tumor cell line KB in culture.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535056

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  2 in total

1.  Variability in DNA minor groove width recognised by ligand binding: the crystal structure of a bis-benzimidazole compound bound to the DNA duplex d(CGCGAATTCGCG)2.

Authors:  A A Wood; C M Nunn; A Czarny; D W Boykin; S Neidle
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

2.  Identification and characterization of bisbenzimide compounds that inhibit human cytomegalovirus replication.

Authors:  Nicole Falci Finardi; HyeongJun Kim; Lee Z Hernandez; Matthew R G Russell; Catherine M-K Ho; Vattipally B Sreenu; Hannah A Wenham; Andy Merritt; Blair L Strang
Journal:  J Gen Virol       Date:  2021-12       Impact factor: 3.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.